Download 1 CV Prof. Dr. rer. nat. habil. Ulrike Susanne Stein

Prof. Dr. Ulrike Stein
CV
CV
Prof. Dr. rer. nat. habil. Ulrike Susanne Stein
Place of birth:
Family status:
Naumburg/Saale, Germany
Married, 2 children (Philipp Maximilian *1986; Luise Theresa *2005)
Address, work:
Experimental and Clinical Research Center,
Charité Universitätsmedizin Berlin and
Max-Delbrück-Center for Molecular Medicine
Head: Translational Oncology of Solid Tumors
Robert-Rössle-Straße 10, 13125 Berlin, Germany
+49 - 30 - 9406 3432, +49 - 30 - 9406 2780, [email protected]
Tel, Fax, Email:
Occupational Carrier
1979 – 1984
Diploma Student, Biochemistry, Martin-Luther-Universitäy, Halle, Germany
1984 – 1991
PhD Student (and maternal leave)
Central Institute for Cancer Research, Depts Virology and Carcinogenesis, Berlin
1987 – 1991
Postgraduate Education: Specialist for Medicinal Biochemistry,
Academy for Physicians Education, Berlin
1989
Research Stay, one month, Oncological Institute, St. Petersburg, Russia
1990
European Summer School, one month, UICC, Lyon, Frankreich
Fellowship from UICC and Boehringer Ingelheim-Foundation, Stuttgart
1991
PhD in Biochemistry, Dr. rer. nat., Humboldt-University, Berlin
1992 – 1993
Post-Doc, Max-Delbrück-Center for Molecular Medicine, Berlin, Dept. Exp. Tumor Therapy
1994 – 1995
Research Stay, National Cancer Institute, Frederick, MD, USA
Feodor-Lynen-fellowship of the Alexander von Humboldt-Foundation, Bonn, and of the Fogarty
International Center NIH, Bethesda, MD, USA
1996 – 2000
Head: Multidrug resistance
Max-Delbrück-Center for Molecular Medicine, in Research Group Surgical Oncology
1996
Research Stay, one month, National Cancer Institute, Frederick, MD, USA
Fellowship Stifterverbandes für die Deutsche Wissenschaft, Essen
1997
Research Stay, one month, National Cancer Institute, Frederick, MD, USA
Alumni-Fellowship Alexander von Humboldt-Foundation, Bonn
1998
Research Stay, one month, National Cancer Institute, Frederick, MD, USA
Alumni-Fellowship Alexander von Humboldt-Foundation, Bonn
2000 - 2006
Head: Tumor metastasis and therapy response
Robert-Rössle-Hospital, Charité Universitätsmedizin Berlin, in Research Group Surgical Oncology
2001
Research Stay, one month, National Cancer Institute, Frederick, MD, USA
Fellowship Science Applications International Corporation, Frederick, MD, USA
2003
Habilitation in Biochemistry, Charité Universitätsmedizin Berlin
2003
Venia legendi for Biochemistry, Privat-Dozentin, Charité Universitätsmedizin Berlin
2003
Research Stay, one month, National Cancer Institute, Frederick, MD, USA
Fellowship Science Applications International Corporation, Frederick, MD, USA
1
Prof. Dr. Ulrike Stein
CV
2007
Head: Tumor metastasis and therapy response
Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin, and
Max-Delbrück-Center for Molecular Medicine, in Research Group Surgical Oncology
2007
Research Stay, one month, National Cancer Institute, Frederick, MD, USA
Alumni-Fellowship Alexander von Humboldt-Foundation, Bonn
2009
Professorship, Charité Universitätsmedizin Berlin
2011
Research Stay, one month, National Cancer Institute, Frederick, MD, USA
2013
Head: Translational oncology of solid tumors
Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin, and
Max-Delbrück-Center for Molecular Medicine
Scientific awards, selected
2014
Felix Burda Award (Foundation for Prevention and Research of Colorectal Cancer), Berlin
2011
Award 16. World Congress on Advances in Oncology, Rhodos, Greece
2010
Award Berlin-Brandenburgische Akademie der Wissenschaften, funded by the Monika-Kutzner-Foundation
for Cancer Research, Potsdam
2009
Wissenschaftspreis (Science Award) of the German Cancer Society (AIO Arbeitsgemeinschaft Internistische
Onkologie) – preclinical/translational part, Berlin
2009
Award 15. International AEK (Arbeitsgemeinschaft Experimentelle Krebsforschung in the German Cancer
Society) Cancer Meeting, Berlin
2005
Award Epithelial Mesenchymal Transition Conference, Vancouver, BC, Canada
2000
Award 24. German Cancer Congress (Poster) Berlin
1996
Award 22. German Cancer Congress (Poster) Berlin
1994
Award 21. German Cancer Congress (Poster) Berlin
1989
Award of the President of the Academy of Sciences, Halle
1988
Young Researcher Award, Academy of Sciences, Berlin
1985
Young Researcher Award, Academy of Sciences, Berlin
Berlin, March 3 2016
2
Prof. Dr. Ulrike Stein
Publication list
Publication list
Impact Factors per respective year
(for 2015: IF 2014)
ISI Web of Science (3.3.2016):
Hirsch (h) – Index: 31
Personal Scientific Citations (PSI) - Index: 2,653
ResearchGate RG (3.3.2016):
RG Score: 41.97
RG Publications: 171
RG Reads: 4.07 k
RG Citations: 3,206
RG Impact Points: 735.16
Impact Factors, total: 493.994
Original articles and reviews, no published abstracts
Total
First author
Last author
Co-author
Original articles
439.972
147.272
122.557
170.143
Reviews
54.022
10.733
33.960
9.329
Publications, total: 134
Original articles, reviews, books and book chapters, no published abstracts
Total
First author
Last author
Co-author
Original articles
92
27
24
41
Reviews
16
7
6
3
Books
4
0
4
0
Book chapters
22
6
7
9
Total
First author
Last author
Co-author
185
126
42
18
Total
First author
Last author
Co-author
189
49
80
60
Talks, total: 186
invited (US): 108
all
Posters, total: 189
all
1
Prof. Dr. Ulrike Stein
Publication list
Original articles: 92 (IF 439.972)
2016
Lemos C, Hardt M, Juneja M, Voss C, Förster S, Jerchow B, Haider W, Bläker H, Stein U. MACC1 induces tumor progression in
transgenic mice and colorectal cancer patients via increased pluripotency markers Nanog and Oct4.
Clin Cancer Res. 2016 Jan 12. pii: clincanres.1425.2015. [Epub ahead of print] IF 8.722
2015
Schmid F, Wang Q, Huska MR, Andrade-Navarro MA, Lemm M, Fichtner I, Dahlmann M, Kobelt D, Walther W, Smith J, Schlag
PM, Stein U. SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is
prognostic for colorectal cancer patient survival.
Oncogene. 2015 Dec 21. doi: 10.1038/onc.2015.451. [Epub ahead of print] IF 8.459
Walther W, Kobelt D, Bauer L, Aumann J, Stein U. Chemosensitization by diverging modulation by short- and long-term TNFalpha on ABCB1 expression and NFkB signaling in colon cancer.
Int J Onc, 47: 2276-2285, 2015 IF 3.025
Lederer A, Herrmann P, Seehofer P, Dietel M, Pratschke J, Schlag PM, Stein U. MACC1 is an independent prognostic biomarker
for survival in Klatskin tumor patients.
Hepatology, 62:841-850, 2015 IF 11.055
Koelzer VH, Hermann P, Zlobec I, Karamitopoulou E, Lugli A, Stein U. Heterogeneity analysis of Metastasis Associated in Colon
Cancer 1 for survival prognosis of colorectal cancer patients: a retrospective cohort study.
BMC Cancer, 15:160, 2015 IF 3.362
Ilm K, Kemmner W, Osterland M, Koch G, Herrmann P, Schlag PM, Stein U. High MACC1 expression together with mutated
KRAS G13 indicate high risk colorectal cancer.
Mol Cancer, 14:38, 2015 IF 4.257
Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KD, Stein U. Circulating MACC1 transcripts in gastric cancer
patient plasma as diagnostic and prognostic biomarker.
World J Gastroenterol, 21:333-341, 2015 IF 2.369
Medapati MR, Dahlmann M, Ghavami S, Pathak A, Lucman L, Hoang-Vu C, Stein U, Hombach-Klonisch S. RAGE mediates the
pro-migratory response of extracellular S100A4 in human thyroid cancer cells.
Thyroid, 25:514-527, 2015 IF 4.493
Hansen M, Forst B, Cremers N, Quagliata L, Ambartsumian N, Grum-Schwensen B, Klingelhöfer J, Abdul-Al A, Herrmann P,
Osterland M, Stein U, Nielsen G, Scherer P, Lukanidin E, Grigorian M, Sleeman J. A link between inflammation and
metastasis: Serum Amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4.
Oncogene 34:424-435, 2015 IF 8.459
2014
Dahlmann M, Okhrimenko A, Marcinkowski P, Osterland M, Herrmann P, Smith J, Heizmann C, Schlag PM, Stein U. RAGE
mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human
colorectal cancer metastasis.
Oncotarget, 5:3220-3233, 2014 IF 6.359
2013
Hagemann C, Fuchs S, Monoranu CM, Herrmann P, Smith J, Hohmann T, Grabiec U, Kessler AF, Dehghani F, Löhr M, Ernestus
RI, Vince GH, Stein U. Impact of MACC1 on human malignant glioma progression and unfavorable patients’
prognosis.
Neuro-Oncol, 15:1696-1709, 2013 IF 5.286
Juneja M, Ilm K, Schlag PM, Stein U. Promoter identification and transcriptional regulation of the metastasis gene MACC1 in
colorectal cancer.
Mol Oncol, 7:929-943, 2013 IF 5.937
Grabundzija I, Wang, J, Sebe A, Erdei Z, Kajdi R, Devaraj A, Steinemann D, Szuhai K, Stein U, Cantz T, Schambach A, Baum C,
Izsvák Z, Sarkadi B, Ivics Z. Sleeping beauty transposon-based system for cellular reprogramming and targeted gene
insertion in induced pluripotent stem cells.
Nucl Acids Res 41:1829-1847, 2013 IF 8.808
2
Prof. Dr. Ulrike Stein
Publication list
2012
Stein U, Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KW, Schlag PM. Circulating MACC1 transcripts in
colorectal cancer patient plasma predict metastasis and prognosis.
PLoS ONE, 7:e49249, 2012 IF 3.730
Stein U, Fleuter C, Siegel F, Smith J, Kopacek A, Scudiero DA, Hite KM, Schlag PM, Shoemaker RH, Walther W. Impact of mutant
-catenin on ABCB1 expression and therapy response in colon cancer cells
Br J Cancer, 106:1395-1405, 2012 IF 5.082
Nitsche U, Rosenberg R, Balmert A, Schuster T, Slotta-Huspenina J, Herrmann P, Bader FG, Friess H, Schlag PM, Stein U*,
Janssen KP*, *contributed equally Integrative marker analysis allows risk assessment for metastasis in stage II colon
cancer.
Ann Surgery, 256: 763-771, 2012 IF 6.329
Schmid F, Burock S, Klockmeier K, Schlag PM, Stein U. SNPs in the coding region of the metastasis-inducing gene MACC1 and
clinical outcome in colorectal cancer.
Mol Cancer, 2012 11:49, 2012 IF 5.134
Dahlmann M, Sack U, Herrmann P, Lemm M, Fichtner I, Schlag PM, Stein U. Systemic shRNA mediated knock down of S100A4
in colorectal cancer xenografted mice reduces metastasis formation.
Oncotarget, 3: 783-797, 2012 IF 6.636
Pichorner A, Sack U, Kobelt D, Kelch I, Arlt F, Smith J, Walther W, Schlag PM, Stein U. In vivo imaging of colorectal cancer
growth and metastasis by targeting MACC1 with shRNA in xenografted mice.
Clin Exp Metastasis, 29: 573-583, 2012 IF 3.460
Neeb A, Wallbaum S, Novac N, Dukovic-Schulze S, Scholl I, Schreiber C, Schlag P, Moll J, Stein U, Sleeman JP. The immediate
early gene Ier2 promotes tumor cell motility and metastasis, and predicts poor survival of colorectal cancer patients.
Oncogene 31:3796-3806, 2012 IF 7.357
Walther W, Petkov S, Kuvardina ON, Aumann J, Kobelt D, Fichtner I, Lemm M, Piontek J, Blasig IE, Stein U, Schlag PM. Novel
Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3 and -4 overexpressing
tumors.
Gene Ther, 19:494-503, 2012 IF 4.321
2011
Stein U, Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KD, Schlag PM. Diagnostic and prognostic value of
metastasis inducer S100A4 transcripts in plasma of colon, rectal, and gastric cancer patients.
J Mol Diagn, 13:189-198, 2011 IF 3.576
Stein U, Arlt F, Smith J, Sack U, Herrmann P, Walther W, Lemm M, Fichtner I, Shoemaker RH, Schlag PM.
catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis.
Neoplasia, 13:131-144, 2011 IF 5.946
-
Sack U, Walther W, Scudiero D, Selby M, Aumann J, Lemos C, Fichtner I, Schlag PM, Shoemaker RH, Stein U. S100A4-induced
cell motility and metastasis is restricted by the Wnt/b-catenin pathway inhibitor calcimycin in colon cancer cells.
Mol Biol Cell, 22:3344-3354, 2011 IF 4.942
Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M, Fichtner I, Schlag PM, Shoemaker RH, Stein U. Novel effect of
anti-helmintic niclosamide on S100A4-induced metastasis in colon cancer.
J Natl Cancer Inst, 103:1018-1836, 2011 IF 13.757
Thiele W, Novac N, Mink S, Schreiber C, Plaumann D, Fritzmann J, Cremers N, Rothley M, Schwager C, Regiert T, Huber PE,
Stein U, Schlag P, Moll J, Abdollahi A, Sleeman JP. Discovery of a novel tumour metastasis-promoting gene, NVM-1.
J Pathol, 225:96-105, 2011 IF 6.318
2010
Jürchott K, Kuban R-J, Krech T, Blüthgen N, Stein U, Walther W, Friese C, Kielbasa SM, Ungethüm U, Lund P, Knösel K,
Kemmner W, Morkel M, Fritzmann J, Schlag PM, Birchmeier W, Krueger T, Sperleing S, Sers C, Royer H-D, Herzel H,
Schäfer R. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene
signatures in colorectal cancer cells.
Plos Genetics, 6:e1001231(1-19), 2010 IF 9.543
3
Prof. Dr. Ulrike Stein
Publication list
Kobelt D, Aumann J, Fichtner I, Stein U, Schlag PM, Walther W.
Activation of the CMV-IE promoter by hyperthermia in
vitro and in vivo: biphasic heat induction of cytosine deaminase suicide gene expresion.
Mol Biotechnol 46:197-205, 2010
IF 2.091
Müller T, Stein U, Poletti A, Garzia L, Rothley M, Plaumann D, Thiele W, Bauer M, Galasso A, Schlag PM, Pankratz M, Zollo M,
Sleeman JP. ASAP1 promotes tumor cell motility and invasiveness, stimulates metastasis formation in vivo, and
correlates with poor survival in colorectal cancer patients.
Oncogene 29:2393-2403, 2010
IF 7.414
2009
Stein U, Smith J, Walther W, Arlt F. MACC1 controls Met – what a difference an Sp1 site makes.
Cell Cycle, 8:2467-2469, 2009 IF 4.087
Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, Schlag PM. MACC1, a newly identified key regulator
of HGF/Met signaling, predicts colon cancer metastasis.
Nature Med 15:59-67, 2009 IF 27.136
Fritzmann J, Morkel M, Besser D, Budczies J, Kosel F, Brembeck F, Stein U, Fichtner I, Schlag PM, Birchmeier W. BAMBI links
Wnt/β-catenin and TGFβ signaling in colorectal cancer metastasis.
Gastroenterol 137:165-175, 2009 IF 12.899
2008
Stein U, Walther W, Stege A, Kaszubiak A, Fichtner I, Lage H. Complete in vivo reversal of the multidrug resistance (MDR)
phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA.
Mol Ther 16:178-186, 2008 IF 5.970
Walther W, Siegel R, Kobelt D, Knösel T, Dietel M, Bembenek A, Schleef M, Baier R, Stein U, Schlag PM. Nonviral intratumoral
jet-injection gene transfer in metastatic melanoma and breast cancer: results of a phase I trial.
Clin Cancer Res 14:7545-7553, 2008 IF 6.488
2007
Walther W, Arlt F, Fichtner I, Aumann J, Stein U, Schlag PM. Heat-inducible in vivo gene therapy of colon carcinoma by human
mdr1 promoter regulated TNF- expression.
Mol Cancer Ther 6:237-243, 2007 IF 4.800
2006
Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birchmeier W, Schlag PM,
Shoemaker RH. The metastasis-catenin / T-cell factor (TCF) signaling in
colon cancer.
Gastroenterol 131:1486-1500, 2006 IF 12.457
Walther W, Minow T, Martin R, Fichtner I, Schlag PM, Stein U. Uptake, biodistribution and time course of naked plasmid DNA
trafficking after intratumoral in vivo jet-injection.
Hum Gene Ther 17:611-624, 2006 IF 4.514
2005
Stein U, Bergmann S, Scheffer GL, Scheper RJ, Royer HD, Schlag PM, Walther W. YB-1 facilitates basal and 5-fluorouracilinduced expression of major vault protein (MVP) gene.
Oncogene 24:3606-3618, 2005 IF 6.872
Györffy B, Serra V, Jürchott K, Garber M, Stein U, Petersen I, Lage H, Dietel M, Schäfer R. Prediction of doxorubicin sensitivity in
breast tumors based on gene expression profiles of drug resistant cell lines correlates with patient survival.
Oncogene 24:7542-7551, 2005 IF 6.495
Walther W, Stein U, Fichtner I, Aumann J, Arlt F, Schlag PM. Nonviral jet-Injection gene transfer for efficient in vivo cytosine
deaminase suicide gene therapy of colon carcinoma.
Mol Ther 12:1176-1184, 2005 IF 5.443
Walther W, Stein U, Siegel R, Fichtner I, Schlag PM. Use of the nuclease inhibitor aurintricarboxylic acid (ATA) for improved
non-viral intratumoral in vivo gene transfer by jet-injection.
J Gene Med 7:477-485, 2005 IF 3.699
2004
Walther W, Stein U, Fichtner I, Schlag PM. Low-volume jet-injection for efficient nonviral in vivo gene tranfer.
Mol Biotechnol 28:121-128, 2004 IF 1.614
4
Prof. Dr. Ulrike Stein
Publication list
Knösel T, Schlüns K, Stein U, Schwabe H, Schlag PM, Dietel M, Petersen I. Chromosomal alterations during lymphatic and liver
metastasis formation of colorectal cancer.
Neoplasia 6:23-28, 2004 IF 4.377
Kupsakova I, Rybar A, Docolomansky P, Drobna Z, Stein U, Walther W, Barancik M, Breier A. Reversal of P-glycoprotein
mediated vincristine resistance of L1210/VCR cells by analogues of pentoxifylline. A QSAR study.
Eur J Pharmaceut Science 21:283-293, 2004 IF 1.949
Knösel T, Yu Y, Stein U, Schwabe H, Schlüns K, Schlag PM, Dietel M, Petersen I. Overexpression of cyclooxygenase-2 correlates
with chromosomal gain at the cyclooxygenase-2 locus and decreased patient‘s survival in advanced colorectal
carcinomas.
Dis Colon Rectum 47:70-77, 2004 IF 2.343
2003
Fitze G, Appelt H, König IR, Görgens H, Stein U, Walther W, Gossen M, Schreiber M, Ziegler A, Roesner D, Schackert HK.
Functional haplotypes of the RET proto-oncogene promoter are associated with Hirschsprung disease (HSCR).
Hum Mol Genetics 12:3207-3214, 2003 IF 8.597
Knösel T, Schlüns K, Stein U, Schwabe H, Schlag PM, Dietel M, Petersen I. Genetic imbalances with impact on survival in
colorectal cancer patients.
Histopathol 43:323-331, 2003 IF 2.952
Jürchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I, Piaggio G, Fietze E, Dietel M, Royer HD. YB-1 as cell cycle
regulated transcription factor facilitating cyclin A and cyclin B1 gene expression.
J Biol Chem 278:27988-27996, 2003 IF 6.482
Walther W, Stein U, Voß C, Schmidt T, Schleef M, Schlag PM. Stability analysis for long-term storage of naked DNA: impact on
non-viral in vivo gene transfer.
Anal Biochem 318:230-235, 2003 IF 2.174
2002
Stein U, Jürchott K, Schläfke M, Hohenberger P. Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined
sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma
patients.
J Clin Oncol 20:3282-3292, 2002 IF 10.864
Stein U, Lage H, Jordan A, Walther W, Bates SE, Litman T, Hohenberger P, Dietel M. Impact of BCRP/MXR, MRP1, and MDR1/Pglycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Int J Cancer 97:751-760, 2002 IF 4.056
Knösel T, Yu Y, Stein U, Schwabe H, Schlüns K, Schlag PM, Dietel M, Petersen I. Overexpression of c-erbB-2 protein correlates
with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas.
Clin Exp Metast 19:401-407, 2002 IF 2.080
Kowalski P, Stein U, Scheffer GL, Lage H. Moduation of the atypical multidrug–resistant phenotype by a hammerhead ribozyme
directed against the ABC transporter BCRP/MXR/ABCG2.
Cancer Gene Ther 9:579-586, 2002 IF 2.929
Walther W, Stein U, Fichtner I, Voß C, Schmidt T, Schleef M, Nellesen T, Schlag PM. Intratumoral low volume jet-injection for
efficient nonviral gene transfer.
Mol Biotechnol 21:105-115, 2002 IF 1.000
Drobna Z, Stein U, Walther W, Barancik M, Breier A. Pentoxifylline influences drug transport activity of P-glycoprotein and
decreases mdr1 gene expression in multidrug resistant mouse leukemic L1210/VCR cells
Gen Physiol Biophys 21:103-109, 2002 IF 0.719
Knösel T, Petersen S, Schwabe H, Schlüns K, Stein U, Schlag PM, Dietel M, Petersen, I. Incidence of chromosomal imbalances in
advanced colorectal carcinomas and their metastases.
Virchows Arch 440:187-194, 2002 IF 2.045
Walther W, Stein U, Schlag PM. Use of the human MDR1 promoter for heat-inducible expression of therapeutic genes.
Int J Cancer 98:291-296, 2002 IF 4.056
5
Prof. Dr. Ulrike Stein
Publication list
2001
Stein U, Jürchott K, Walther W, Bergmann S, Schlag PM, Royer HD. Hyperthermia-induced nuclear translocation of
transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters.
J Biol Chem 276:28562-28569, 2001 IF 7.258
Walther W, Stein U, Fichtner I, Schlag PM. In vivo gene transfer of naked DNA into xenotransplanted colon carcinoma by jetinjection.
Langenbecks Arch Surgery 30:69-72, 2001 IF 1.538
Walther W, Stein U, Fichtner I, Malcherek L, Lemm M, Schlag PM. Nonviral in vivo gene delivery into tumors using a novel lowvolume jet-injection technology.
Gene Ther 8:173-180, 2001 IF 5.893
2000
Lange C, Walther W, Schwabe H, Stein U. Cloning and initial analysis of the human multidrug resistance-related MVP/LRP gene
promoter.
Biochem Biophys Res Comm 278:125-133, 2000 IF 3.055
Schwabe H, Stein U, Walther W. High-copy cDNA amplification of minimal total RNA quantities for gene expression analyses.
Mol Biotechnol 14:165-172, 2000 IF 0.847
Cartier R, Ren SV, Walther W, Stein U, Lewis A, Schlag PM, Li M, Furth PA. In vivo gene transfer by low-volume jet injection.
Anal Biochem 282:262-265, 2000 IF 1.976
Walther W, Stein U, Fichtner I, Alexander M, Shoemaker RH, Schlag PM. mdr1 promoter-driven tumor necrosis factor-controllable combined in vivo gene therapy and chemotherapy of tumors.
Cancer Gene Ther 7:893-900, 2000 IF 4.151
1999
Stein U, Eder C, Karsten U, Haensch W, Walther W, Schlag PM. Gli gene expression in bone and soft tissue sarcomas of adult
patients correlates with tumor grade.
Cancer Res 59:1890-1895, 1999 IF 8.614
Stein U, Rau B, Wust P, Walther W, Schlag PM. Hyperthermia for treatment of rectal cancer: evaluation for induction of
multidrug resistance gene (mdr1) expression.
Int J Cancer 80:5-12, 1999 IF 3.545
Walther W, Stein U. Therapeutic genes for cancer gene therapy.
Mol Biotechnol 13:21-28, 1999 IF 0.939
1998
Stein U, Walther W. Cytokine-mediated reversal of multidrug resistance.
Cytotechnol 27:271-282, 1998 IF 0.616
Stein U, Walther W, Shoemaker RH, Schlag PM. IL-2 gene transfer for chemosensitization of multidrug-resistant human colon
carcinoma cells.
Adv Exp Med Biol 451:145-149, 1998 IF 0.360
Walther W, Stein U, Fichtner I, Naundorf H, Alexander M, Shoemaker RH, Schlag PM. In vivo evaluation of a drug-inducible
vector system for the combined gene and chemotherapy of cancer.
Adv Exp Med Biol 451:139-144, 1998 IF 0.360
1997
Stein U, Walther W, Lemm M, Naundorf H, Fichtner I. Development and characterisation of novel human multidrug resistant
mammary carcinoma lines in vitro and in vivo.
Int J Cancer 72:885-891, 1997 IF 3.362
Stein U, Walther W, Wendt J, Schild TA. In situ PCR/ RT-PCR by using fluorescence-labeled primers.
BioTechniques 23:194-198, 1997 IF 1.946
Stein U, Walther W, Shoemaker RH. Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach
for reversal of multidrug resistance.
Biother Cancer 1:53, 1997 IF 0.781
6
Prof. Dr. Ulrike Stein
Publication list
Stein U, Walther W, Laurencot CM, Scheffer GL, Scheper RJ, Shoemaker RH. Tumor necrosis factormultidrug resistance-associated genes LRP and MRP.
J Natl Cancer Inst 89:807-813, 1997 IF 11.430
Walther W, Wendt J, Stein U. Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic
genes in cancer gene therapy.
Gene Ther 4:544-552, 1997 IF 7.410
1996
Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon
carcinoma cells.
J Natl Cancer Inst 88:1383-1392, 1996 IF 10.328
Stein U, Walther W, Shoemaker RH. Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach
for reversal of multidrug resistance.
Br J Cancer 74:1384-1391, 1996 IF 3.666
Stein U, Walther W, Shoemaker RH. Vincristine induction of mutant and wild-type human multidrug-resistance promoters is
cell-type-specific and dose-dependent.
J Cancer Res Clin Oncol 122:275-282, 1996 IF 1.093
Stein U, Shoemaker RH., Schlag PM. MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and
chemotherapy of bone and soft tissue sarcomas.
Eur J Cancer 32A:86-92, 1996IF 2.017
Walther W, Stein U. Targeted vectors for gene therapy of cancer and retroviral infections.
Mol Biotechnol 6:267-286, 1996 IF 0.871
Walther W, Stein U. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting.
J Mol Med 74:379-392, 1996 IF 1.769
1995
Walther W, Stein U, Pfeil D. Gene transfer of human TNF alpha into glioblastoma cells permits modulation of mdr1 expression
and potentiation of chemosensitivity.
Int J Cancer 61:832-839, 1995 IF 3.403
1994
Stein U, Walther W, Wunderlich V. Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro
responsiveness to multidrug resistance relevant drugs.
Eur J Cancer 30A:1541-1545, 1994 IF 0.789
Wunderlich V, Stein U. Synergistic effect of tamoxifen and phorbol ester TPA on retrovirus synthesis in a human mammary
carcinoma cell line.
Int J Cancer 56:615-616, 1994 IF 3.276
Walther W, Stein U. Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of
MDR relevant drugs.
J Cancer Res Clin Oncol 120:471-478, 1994 IF 1.654
Fichtner I, Stein U, Hoffmann J, Winterfeld G, Pfeil D, Hentschel M. Characterization of four drug-resistant P 388 sublines:
resistance, sensitivity in vivo, resistance- and proliferation markers, immunogenicity.
Anticancer Res 14:1995-2004, 1994 IF 1.049
Pfeil D, Bergmann J, Fichtner I, Stein U, Hentschel M, Rothe I, Goan SR. Multidrug resistance of murine leukemia cells characterization and correlation to cytochrome P-450 dependent activities, cytosolic calcium, and cell cycle state.
Anticancer Res 14:571-576, 1994 IF 1.049
Walther W, Stein U, Eder C. RNA analysis using miniprep RNA in RT-PCR.
BioTechniques 17:674-675, 1994 IF 1.946
1993
Stein U, Wunderlich V, Haensch W, Schmidt-Peter P. Expression of the mdr1 gene in bone and soft tissue sarcomas of adult
patients.
Eur J Cancer 29A:1979-1981, 1993 IF 0.789
7
Prof. Dr. Ulrike Stein
Publication list
Walther W, Stein U, Uckert W. Rapid method of total RNA mini-preparation from eucaryotic cells.
Nucl Acids Res 21:1682, 1993IF 4.488
1992
Stein U, Wunderlich V, Uckert W. Inhibition of the TPA-induction of simian sarcoma virus by an antisense v-jun oncogene.
Arch Geschwulstforsch 2:163-169, 1991 IF 0.900
1987
Uckert W, Wunderlich V, Fiebach H, Hertling I, Stein U, Kraft R, Desrosiers R. Biochemical and immunochemical
characterization of structural proteins from retroviruses-D/New England and comparison to Mason-Pfizer monkey
virus and permanent human fibroblast virus.
Arch Virol 94:267-282, 1987 IF 1.498
Reviews: 16 (IF 54.022)
2016
Mudduluru G, Walther W, Kobelt D, Dahlmann M, Treese C, Stein U. Repositioning of drugs for intervention in tumor
progression and metastasis: old drugs for new targets.
Drug Resistance Updates, invited review, under review IF 9.121
2015
Böck BC, Stein U, Schmitt CA, Augustin HG. Mouse models of human cancer.
Cancer Res 74:4671-4675, 2014 IF 9.329
2013
Stein U. MACC1 - a novel target for solid cancers.
Expert Opin Ther Targets 17:1039-1052, 2013 Editorial Highlight for September 2013 IF 4.901
Lemos C, Sack U, Schmid F, Juneja M, Stein U. Anti-metastatic treatment in colorectal cancer: Targeting signaling pathways.
Curr Pharm Design 19:841-863, 2013 IF 3.288
2010
Stein U, Dahlmann M, Walther W MACC1 – more than metastasis? Facts and predictions about a novel gene.
J Mol Med 88:11-18, 2010 IF 5.192
2009
Sack U, Stein U. Wnt up your mind – intervention strategies for S100A4-induced metastasis in colon cancer.
Gen Physiol Biophys 28:F55-F64, 2009 IF 0.741
Arlt F, Stein U. Colon cancer metastasis: MACC1 and Met as metastatic pacemakers.
Int J Biochem Cell Biol 41:2356-2359, 2009 IF 4.887
Walther W, Stein U. Heat-responsive gene expression for gene therapy.
Adv Drug Deliv Rev 61:641-649, 2009 IF 11.957
2006
Stein U, Walther W. Current Opinion: Reversal of ABC transporter-mediated multidrug resistance in cancer: A realistic option?
Am J Cancer 5:285-297, 2006
Stein U, Walther W, Schlag PM. Mutidrug resistance – cellular transport problems and consequences.
Pädiatr Praxis 68:11-22, 2006
2005
Stein U, Walther W, Schlag PM. Mutidrug resistance – cellular transport problems and consequences.
Tägl Praxis 46:125-133, 2005
2004
Walther W, Stein U, Schlag PM. Gene therapy strategies for tumor diseases.
Pädiatr Praxis 65:399-406, 2004
2003
Stein U, Walther W, Schlag PM. Mutidrug resistance – cellular transport problems and consequences.
Chirurg Praxis 62:215-223, 2003
8
Prof. Dr. Ulrike Stein
Publication list
2002
Walther W, Stein U, Schlag PM. Gene therapy strategies for tumor diseases.
Chirurg Praxis 60:19-26, 2002
2000
Stein U. Editorial. P-glycoprotein turned twenty: Are we any closer to fight drug resistance in cancer?
Onkol 23:316-317, 2000 IF 0.640
Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases.
Drugs 60:249-271, 2000 IF 3.966
Books: 4
2015
Walther W, Stein U (editors)
Gene therapy of solid cancers. Methods and protocols.
Methods in molecular biology.
ed. by Walther W, Stein U.
Springer/Humana Press, New York, NY, 1-585, 2015. ISBN 978-1-4939-2726-5
2009
Walther W, Stein U (editors)
Gene therapy of cancer: Methods and protocols.
Methods in molecular biology.
Springer/Humana Press, New York, NY, 1-717, 2009. ISBN 978-1-934115-85-5
2007
Schlag PM, Stein U (editors)
Regional cancer therapy.
Cancer drug discovery and development.
Humana Press, Totowa, NJ, 1-455, 2007. ISBN 978-1-58829-672-6
2000
Walther W, Stein U (editors)
Gene therapy of cancer: Methods and protocols.
Methods in molecular medicine. Vol. 35
Humana Press, Totowa, NJ, 1-616, 2000. ISBN 0-89603-714-2
Book chapters: 22
2016
Mudduluru G, Ilm K, Dahlmann M, Stein U. MACC1, a novel player in solid cancer carcinogenesis.
In: Molecular mechanisms in carcinogenesis
ed. By Haybäck J.
Springer, in press
2015
Dahlmann M, Stein U. RNA interference for antimetastatic therapy.
In: Gene therapy of solid cancers. Methods and protocols. Methods in molecular biology. Vol. 1317.
ed. by Walther W, Stein U.
Springer/Humana Press, New York, NY, 153-165, 2015. ISBN 978-1-4939-2726-5
2013
Kobelt D, Aumann J, Schleef M, Schmeer M, Stein U, Schlag PM, Walther W. Minicircle-based vectors for non-viral gene
therapy: in vitro characterization and in vivo application.
In: Minicircle and Miniplasmid DNA vectors: The future of non-viral gene transfer
ed. Schleef M.
Wiley VCH Verlag; Weinhein, 177-188, 2013. ISBN 978-3-527-32456-9
9
Prof. Dr. Ulrike Stein
Publication list
2012
Stein U. Gutartiges und bösartiges Wachstum von Säugerzellen: MACC1 – ein neu identifiziertes Gen ist ein Schlüsselmolekül
für bösartiges Wachstum und Metastasierung.
In: Nova Acta Leopoldina Vol. 393
eds. Wobus AM, Wobus U, Parthier B.
Deutsche Akademie der Naturforscher Leopoldina, Halle/Saale, 101-114, 2012. ISBN 978-3-8047-3059-5
2011
Walther W, Schlag PM, Stein U. Local gene delivery for therapy of solid tumors.
In: Drug delivery in oncology. From research concepts to cancer therapy.
ed. Kratz F, Senter P, Steinhagen H.
Wiley-VCH, Weinheim, 1391-1414, 2011. ISBN 978-3-527-32823-9
2010
Walther W, Stein U, Lage H. Jet-injection of short hairpin RNA-encoding vectors into tumor cells.
In: RNA Therapeutics: Function, design, and delivery. Methods in molecular biology. Vol. 629
ed. by Sioud M.
Springer/Humana Press, New York, NY, 121-137, 2010. ISBN 978-1-60761-656-6
2009
Walther W, Fichtner I, Schlag PM, Stein U. Nonviral jet-injection technology for intratumoral in vivo gene transfer of naked
DNA.
In: Gene therapy of cancer. Methods in molecular biology. Vol.542
ed. by Walther W, Stein U.
Springer/Humana Press, New York, NY, 195-208, 2009. ISBN 978-1-934115-85-5
2008
Graschew G, Smith J, Rakowsky S, Roelofs TA, Schlag PM, Stein U. Improved tumor response by laser light treatment.
In: Biophotonics. Photonic solutions for better healthcare. Vol. 6991
ed. by Popp J, Drexler W, Tuchin VV, Matthews DL.
SPIE Publications, 69911A1-4, 2008. ISBN 978-0-819-47189-5 IF 0.2
Siegel R., Kobelt D, Knösel T, Stein U, Schlag PM, Walther W. Local nonviral intratumoral jet-injection gene transfer in
metastatic melanoma and breast cancer: results of a phase I trial.
In: Chir Forum. Vol. 37
ed. by Arbogast R, Schackert HK, Bauer H..
Springer-Verlag, Berlin, 131-132, 2008. ISBN 978-3-540-78821-8
2007
Stein U, Schlag PM. Clinical, biological, and molecular aspects of metastasis in colorectal cancer.
In: Recent Results in Cancer Research – Targeted therapies in cancer. Vol. 176
ed. by Dietel M.
Springer-Verlag, Heidelberg, 61-80, 2007. ISBN 978-3-540-46090-9
Stein U, Walther W, Schlag PM. Multidrug resistance - clinical implications for regional cancer therapy.
In: Regional cancer therapy. Cancer drug discovery and development.
ed. by Schlag PM, Stein U.
Humana Press, Totowa, NJ, 3-18, 2007. ISBN 978-1-58829-672-6
Walther W, Stein U, Schlag PM. Local Gene Therapy for Cancer.
In: Regional cancer therapy. Cancer drug discovery and development.
ed by Schlag PM, Stein U.
Humana Press, Totowa, NJ, 181-196, 2007. ISBN 978-1-58829-672-6
Siegel R, Stein U, Kobelt D, Aumann J, Schlag PM, Walther W. Early results of a phase-I-clinical trial of nonviral gene ransfer by
jet-injection into cutaneous lesions of metastatic breast cancer and in-transit lesions of metastatic melanoma.
In: Chir Forum. Vol. 36
ed. by Steinau HU, Schackert HK, Bauer H.
Springer Verlag, Berlin, 441-443, 2007. ISBN 978-3-540-71122-3
10
Prof. Dr. Ulrike Stein
Publication list
2006
Stein U. Multidrug resistance
In: Encyclopedic reference of genomics and proteomics in molecular medicine.
ed. by Ganten D, Ruckpaul K.
Springer, Berlin Heidelberg New York,1208-1212, 2006. ISBN 3-540-44244-8
2005
Walther W, Stein U. Needleless jet-injection of naked DNA for nonviral in vivo gene transfer.
In: DNA-Pharmaceuticals
ed. by Schleef M.
Wiley-VCH, Weinheim, 133-143, 2005. ISBN 3-527-31187-4
2000
Walther W, Stein U, Shoemaker RH, Schlag PM. Chemotherapy-inducible vector for gene therapy of cancer.
In: Gene therapy of cancer: Methods and protocols. Methods in molecular medicine. Vol. 35
ed. by Walther W, Stein U.
Humana Press, Totowa, NJ, 371-392, 2000. ISBN 0-89603-714-2
1998
Stein U, Walther W. Cytokine-mediated reversal of multidrug resistance.
In: Multiple drug resistance in cancer 2. Molecular, Cellular and Clinical Aspects.
ed. by Clynes M.
Kluwer Academic Publishers, Dordrecht, 271-282, 1998. ISBN 0-7923-5272-6
Stein U, Walther W, Shoemaker RH, Schlag PM. IL-2 gene transfer for chemosensitization of human colon carcinoma cells.
In: Advances in Experimental Medicine and Biology: Gene Therapy of Cancer.
ed. by Walden P, Trefzer U, Sterry W, Farzaneh F.
Plenum Publishing Corporation, London, 451:145-149, 1998. ISBN 978-0-306-46027-2
Uckert W, Walther W, Stein U. Large and small scale RNA preparations from eucaryotic cells.
In: Methods in Molecular Biology: RNA isolation and characterization protocols. Vol. 86
ed. by Rapley R, Manning D.
Humana Press,Totowa, NJ, 7-14, 1998. ISBN 978-0-89603-494-5
Walther W, Stein U, Fichtner I, Naundorf H, Alexander M, Shoemaker RH, Schlag PM. In vivo evaluation of a drug-inducible
vector system for the combined gene and chemotherapy of cancer.
In: Advances in Experimental Medicine and Biology: Gene Therapy of Cancer. Vol. 451
ed. by Walden P, Trefzer U, Sterry W, Farzaneh F.
Plenum Publishing Corporation, London, 139-144, 1998. ISBN 978-0-306-46027-2
1996
Hoffmann J, Stein U, Schmidt-Peter P, Haensch W, Naundorf H, Scheper RJ, Fichtner I. Establishment and characterization of
human sarcoma lines transplanted into nude mice.
In: Immunodeficient animals: Models for cancer research. Vol. 51
ed. by Arnold W, Köpf-Maier P, Micheel B.
Contrib Oncol Basel, Karger, 57-60, 1996. ISBN 978-3805562706
1994
Hoffmann J, Stein U, Schmidt-Peter P, Haensch W, Naundorf H, Fichtner I. Development and characterization of in vivo and in
vitro tumor lines for investigation of the phenomenon of multidrug resistance in human sarcomas.
In: Recent Advances in Chemotherapy.
ed. by Einhorn J, Nord CE, Norrby SR.
ASM Press, Washington DC, 885-887,1994. ISBN 978-1555810740
11
Prof. Dr. Ulrike Stein
Statement
Standing as a candidate for the Metastasis Research Society Board - Europe
Herewith I would like to apply for the vacant position of a regular MRS Board Member, based in Europe,
for a term of four years.
Since the beginning of my occupational carrier, I am working in the field of translational oncology; in
the first years, I focused on cancer drug resistance, its molecular mechanisms and
circumvention/overcoming strategies. Since about 10 years, I concentrate my scientific efforts on
research on metastasis of solid tumors. Metastatic dissemination of primary tumors is directly linked to
patient survival and critically limits successful therapy in many tumor entities. Thus, the translational
concepts of my group Translational Oncology of Solid Tumors aim at the identification of key molecules
in tumor progression and metastasis for improved prognosis and therapy of solid cancers. In recent
years, we newly discovered the previously undescribed gene MACC1 (metastasis-associated in colon
cancer 1). MACC1 has been meanwhile acknowledged as prognostic and in part also as predictive
biomarker for a broad variety of solid cancers by numerous other groups. We demonstrated MACC1,
S100A4 and transcriptional targets or protein binding partners thereof as new diagnostic, prognostic
and predictive key players for tumor progression and metastasis. Biomarker development was done in
established and patient-derived 3D cultures, cell line-derived and patient-derived xenografts (PDX) and
newly generated genetically engineered mouse models. We exploited this knowledge for improved
disease prognosis and treatment response prediction in tissue and blood of cancer patients. Novel
therapeutic approaches are currently tested in preclinical trials at the transcriptional, posttranscriptional, translational, post-translational and at the structural levels. Most promising strategies
are currently being tested in clinical trials to treat patients with metastatic disease using small molecule
inhibitors acting on these biomarkers.
Thus, based on my scientific background, I would like to stand as a candidate for the Metastasis
Research Society Board – Europe. Since the success of the MRS is strongly dependent on the active
participation and time investment of the members of its executive board I understand the strong
commitment which is expected to be provided by the board members.
I would like to contribute to the enhancement of the visibility of the MRS, e.g. by pro-actively
contributing in coordinating and organizing society activities to increase both the public awareness of
the need for research on metastasis and the interdisciplinary networking of researchers and clinicians
worldwide. Although our understanding of the biology of the metastatic process has certainly been
improved in recent years, there are still ambitous challenges for e.g. signaling-driven interventions and
their clinical translations desired. Thus, it would be very beneficial to initiate clinical trials focused on
metastasis since although there is a decisive impact of the metastatic disease on cancer patient
survival, clinical trials for new or repositioned anti-cancer/anti-metastatic drugs together with
appropriate clinical trial designs are needed. Here, the involvement of clinicians and the pharmaceutical
industry in the MRS is very welcome. Further, among all the points I would like to mention, I would like
to focus on the official scientific journals of the MRS. It would be my pleasure to contribute to further
improve the impact of these journals simultaneously reflecting the visibility of the MRS and the
importance of research in the field of metastasis. Thereby, not only the knowledge will be spread, but
also the number of new MRS members as well as of attracting young metastasis researchers might be
increased. And certainly, I will take to chance to become an active part of the society`s Working groups.
I am thankful and I feel honored for the possibility to apply to stand as a candidate for the Metastasis
Research Society Board – Europe. I would like to express my willingness to support the MRS to increase
its reputation and impact for better understanding metastasis as a biological process and for improved
translation to better meet patients needs.
1